Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
29.43
0.00 (0.00%)
Aug 24, 2026, 9:31 AM EDT - Market open

Maze Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22
1,6351,994---
Market Cap Growth
176.57%----
Enterprise Value
1,2001,634---
Last Close Price
29.4341.43---

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22
PB Ratio
3.605.62---
P/TBV Ratio
3.615.62---

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22
Debt / Equity Ratio
0.130.070.144.940.32
Debt / EBITDA Ratio
--0.40--
Debt / FCF Ratio
--0.36--
Net Debt / Equity Ratio
-0.96-0.90-0.862.04-0.67
Net Debt / EBITDA Ratio
3.022.27-2.79-0.220.63
Net Debt / FCF Ratio
4.072.83-2.27-0.230.67
Asset Turnover
0.05-1.07--
Quick Ratio
18.0315.239.521.794.81
Current Ratio
18.3115.509.762.095.11
Return on Equity (ROE)
-37.35%-47.52%50.48%-180.12%-
Return on Assets (ROA)
-21.79%-28.01%23.07%-55.63%-
Return on Invested Capital (ROIC)
-190.34%-453.11%196.80%-307.50%-330.64%
Return on Capital Employed (ROCE)
-28.60%-38.20%26.20%-178.60%-86.00%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22
Earnings Yield
-8.17%-6.58%---
FCF Yield
-6.54%-5.66%---
Buyback Yield / Dilution
-174.46%-1474.04%-19.33%-13.82%-
SEC Filings: 10-K · 10-Q